Tempest Therapeutics (TPST) Depreciation & Amortization (CF) (2012 - 2026)
Tempest Therapeutics (TPST) posted Depreciation & Amortization (CF) of $65000.0 for Q4 2025, down 1.52% sequentially from $66000.0 in Q3 2025, and up 32.65% YoY from $49000.0 in Q4 2024.
Tempest Therapeutics (TPST) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $65000.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 32.65% year-over-year to $65000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $266000.0 (down 31.79% YoY) and the FY2025 annual result came in at $266000.0, down 31.62% from the prior year.
- Depreciation & Amortization (CF) eased to $65000.0 in Q4 2025 per TPST's latest filing, from $66000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $217000.0 in Q4 2022 and troughed at $49000.0 in Q4 2024.
- A 5-year average of $102400.0 and a median of $88000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) surged 112.75% in 2022, then sank 60.83% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $102000.0 in 2021, then soared by 112.75% to $217000.0 in 2022, then tumbled by 60.83% to $85000.0 in 2023, then plunged by 42.35% to $49000.0 in 2024, then surged by 32.65% to $65000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $65000.0, $66000.0, and $67000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59,000.00 |
| Jun 30, 2026 | 59,000.00 |
| Dec 31, 2025 | 65,000.00 |
| Dec 31, 2025 | 65,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Dec 31, 2023 | 85,000.00 |